NEW YORK (GenomeWeb) – ThermaGenix has signed a global distribution agreement for its PCR improvement reagents with MilliporeSigma, the US operation of Merck KGaA's life science business.
Terms of the deal were not disclosed.
The agreement covers the sale of ThermaGenix's ThermaStop, ThermaGo, and ThermaStop-RT reagents for improving the specificity and fidelity of Taq polymerase and reverse transcriptase, particularly in qPCR, RT-PCR, multiplexing, and preparation of DNA amplicons for next-generation sequencing, the firm said. They will now be available from MilliporeSigma's global sales force and website.
ThermaGenix licensed one of the technologies underlying its products from Brandeis University last year, and subsequently completed a $1.5 million series A-1 financing round.